ALBIREO PHARMA INC's ticker is ALBO and the CUSIP is 01345P106. A total of 114 filers reported holding ALBIREO PHARMA INC in Q3 2020. The put-call ratio across all filers is 7.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $66 | -99.9% | 3,087 | -47.4% | 0.00% | – |
| Q3 2022 | $113,000 | 0.0% | 5,865 | +3.0% | 0.00% | – |
| Q2 2022 | $113,000 | +334.6% | 5,694 | +406.1% | 0.00% | – |
| Q4 2021 | $26,000 | -10.3% | 1,125 | +34.7% | 0.00% | – |
| Q3 2021 | $29,000 | 0.0% | 835 | 0.0% | 0.00% | – |
| Q2 2021 | $29,000 | -74.3% | 835 | -74.2% | 0.00% | – |
| Q1 2021 | $113,000 | +438.1% | 3,234 | +477.5% | 0.00% | – |
| Q4 2020 | $21,000 | -97.7% | 560 | -98.0% | 0.00% | -100.0% |
| Q3 2020 | $919,000 | +371.3% | 27,543 | +274.1% | 0.00% | – |
| Q2 2020 | $195,000 | +126.7% | 7,363 | +39.8% | 0.00% | – |
| Q1 2020 | $86,000 | +1620.0% | 5,265 | +2150.0% | 0.00% | – |
| Q4 2019 | $5,000 | -90.7% | 234 | -91.4% | 0.00% | – |
| Q3 2019 | $54,000 | +285.7% | 2,716 | +521.5% | 0.00% | – |
| Q1 2019 | $14,000 | 0.0% | 437 | -26.1% | 0.00% | – |
| Q4 2018 | $14,000 | – | 591 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 174,791 | $6,556,000 | 3.03% |
| Sio Capital Management, LLC | 354,210 | $13,286,000 | 2.72% |
| Birchview Capital, LP | 92,000 | $3,451,000 | 1.99% |
| Chicago Capital, LLC | 618,263 | $23,191,000 | 1.04% |
| Perceptive Advisors | 2,360,139 | $88,529,000 | 0.95% |
| Endurant Capital Management LP | 42,292 | $1,586,000 | 0.57% |
| Artal Group S.A. | 700,000 | $26,257,000 | 0.56% |
| Cormorant Asset Management, LP | 500,000 | $18,755,000 | 0.45% |
| Samsara BioCapital, LLC | 100,000 | $3,751,000 | 0.38% |
| RICE HALL JAMES & ASSOCIATES, LLC | 257,372 | $9,654,000 | 0.34% |